NICaS provides a real-time, continuously accurate1,2,3 and highly reproducible4 hemodynamic status including: stroke volume, cardiac output, total peripheral resistance, cardiac power index and total body water.

NICaS can help you:

  • Assess inclusion criteria
  • Obtain real-time dose titration information
  • Monitor cardiac safety in both cardiovascular and non-cardiovascular trials
  • Evaluate drug efficacy and safety
  • Support single or multi-site clinical trials
  • Document desired and adverse effects of candidate compounds
  • Reduce total trial time by facilitating patient recruitment
  • Decrease time-to-market of successful compounds


NICaS unique technology:

  • Allows easy application with only two sensors
  • Secure the data transfer to the core lab
  • Accurately assess the smallest hemodynamic changes
  1. Paredes OL, Shite J, Shinke T, et al. Impedance cardiography for cardiac output estimation: reliability of wrist-to-ankle electrode configuration. Circ J. 2006;70(9):1164-1168. doi:10.1253/circj.70.1164
  2. Cotter G, Schachner A, Sasson L, Dekel H, Moshkovitz Y. Impedance cardiography revisited. Physiol Meas. 2006;27(9):817-827. doi:10.1088/0967-3334/27/9/005
  3. Cotter G, Moshkovitz Y, Kaluski E, et al. Accurate, noninvasive continuous monitoring of cardiac output by whole-body electrical bioimpedance. Chest. 2004;125(4):1431-1440. doi:10.1378/chest.125.4.1431
  4. Tita C, Gilbert EM, Van Bakel AB, et al. A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction. Eur J Heart Fail. 2017;19(10):1321-1332. doi:10.1002/ejhf.897